Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.07
-14.6%		$0.07
$0.03
▼
$0.11
$772K1.5224,789 shs2,711 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.59
-11.9%		$0.28
$0.00
▼
$1.00
$3.05M3.16959 shs100 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$1.76
-9.3%		$3.56
$1.63
▼
$15.15
$3.08M0.6639,430 shs80,709 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$4.68
-1.7%		$5.95
$2.98
▼
$80.10
$2.69M2.8126,850 shs9,645 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-14.56%+18.42%-10.00%+12.50%+22.28%
Orgenesis Inc. stock logo
ORGS
Orgenesis
-11.86%+31.11%+68.57%+85.30%-34.44%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-9.28%-18.14%-42.67%-71.24%-83.85%
SciSparc Ltd. stock logo
SPRC
SciSparc
-1.68%-5.45%-29.52%-36.84%-71.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.07
-14.6%		$0.07
$0.03
▼
$0.11
$772K1.5224,789 shs2,711 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.59
-11.9%		$0.28
$0.00
▼
$1.00
$3.05M3.16959 shs100 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$1.76
-9.3%		$3.56
$1.63
▼
$15.15
$3.08M0.6639,430 shs80,709 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$4.68
-1.7%		$5.95
$2.98
▼
$80.10
$2.69M2.8126,850 shs9,645 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-14.56%+18.42%-10.00%+12.50%+22.28%
Orgenesis Inc. stock logo
ORGS
Orgenesis
-11.86%+31.11%+68.57%+85.30%-34.44%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-9.28%-18.14%-42.67%-71.24%-83.85%
SciSparc Ltd. stock logo
SPRC
SciSparc
-1.68%-5.45%-29.52%-36.84%-71.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest HEPA, ORGS, SILO, and SPRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
SciSparc Ltd. stock logo
SPRC
SciSparc
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/1/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K4.61N/AN/A($6.58) per share-0.09
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$70K39.98N/AN/A$7.10 per share0.25
SciSparc Ltd. stock logo
SPRC
SciSparc
$860K3.10N/AN/A$12.93 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%10/14/2026 (Estimated)
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36M-$11.51N/AN/AN/A-3,827.81%N/A-130.18%11/11/2026 (Estimated)
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$4.36N/AN/AN/A-6,726.39%-81.75%-66.35%12/2/2026 (Estimated)
SciSparc Ltd. stock logo
SPRC
SciSparc
-$12.18MN/AN/AN/AN/AN/AN/AN/AN/A

Latest HEPA, ORGS, SILO, and SPRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/14/2026N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00-$0.08+$199.92N/AN/AN/A
8/13/2026Q2 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32-$0.76-$0.44-$0.76$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
5.36
5.36
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
2.41
2.38

Institutional Ownership

CompanyInstitutional Ownership
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%

Insider Ownership

CompanyInsider Ownership
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.91%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
SciSparc Ltd. stock logo
SPRC
SciSparc
1.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
Orgenesis Inc. stock logo
ORGS
Orgenesis
1505.17 million4.53 millionNo Data
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
21.59 million1.53 millionNot Optionable
SciSparc Ltd. stock logo
SPRC
SciSparc
4570,000557,000Not Optionable

Recent News About These Companies

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
September 2, 2026  |  thenewswire.comT
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial
September 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scisparcs-neurothera-advances-enrollment-in-sci-210-autism-trial?utm_source=marketbeat.com&utm_medium=referral
SciSparc Subsidiary Pursues FDA Orphan Drug Status For Tourette Syndrome Drug
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687877/scisparc-subsidiary-pursues-fda-orphan-drug-status-for-tourette-syndrome-drug.aspx
SciSparc Subsidiary NeuroThera Pursues FDA Orphan Drug Designation for SCI-110 in Adult Tourette Syndrome
September 2, 2026  |  quiverquant.comQ
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
September 2, 2026  |  thenewswire.comT
SciSparc Ltd: SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial
September 1, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69459881-scisparc-ltd-scisparc-subsidiary-neurothera-labs-achieves-significant-enrollment-momentum-in-sci-210-autism-clinical-trial-399.htm
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353674/0/en/scisparc-subsidiary-neurothera-labs-achieves-significant-enrollment-momentum-in-sci-210-autism-clinical-trial.html
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
August 31, 2026  |  thenewswire.comT
Neurothera Labs Inc. Announces Share Consolidation
August 28, 2026  |  thenewswire.comT
NeuroThera Labs Hires European IR Firm to Expand Investor Reach
August 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=marketbeat.com&utm_medium=referral
NeuroThera Labs Engages Dr. Reuter Investor Relations
August 27, 2026  |  thenewswire.comT
SciSparc Bolsters Agentic AI Push with Appointment of Technion Expert to Advisory Board
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scisparc-bolsters-agentic-ai-push-with-appointment-of-technion-expert-to-advisory-board?utm_source=marketbeat.com&utm_medium=referral
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351350/0/en/scisparc-advances-agentic-ai-strategy-with-addition-of-internationally-recognized-ai-expert-prof-carmel-domshlak-to-scientific-advisory-board.html
SciSparc Highlights NeuroThera-Clearmind MDMA-PEA Patent Milestone Amid New FDA Psychedelic Guidance
August 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scisparc-highlights-neurothera-clearmind-mdma-pea-patent-milestone-amid-new-fda-psychedelic-guidance?utm_source=marketbeat.com&utm_medium=referral
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3349741/0/en/scisparc-neurothera-clearmind-collaboration-advances-mdma-n-acylethanolamines-ip-for-the-treatment-of-ptsd-amid-rising-u-s-federal-support-for-psychedelic-innovation.html
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scisparc-boosts-neurothera-stake-in-c5-4-million-financing?utm_source=marketbeat.com&utm_medium=referral
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
August 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scisparc-subsidiary-neurothera-labs-completes-c-5-4-million-financing-with-scisparc-s-stake-valued-at-approximately-c-30-million-1036470184
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6%
August 18, 2026  |  quiverquant.comQ
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million
August 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/18/3346796/0/en/scisparc-subsidiary-neurothera-labs-completes-c-5-4-million-financing-with-scisparc-s-stake-valued-at-approximately-c-30-million.html
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement
August 17, 2026  |  thenewswire.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.07 -0.01 (-14.56%)
As of 09/16/2026 02:35 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$0.59 -0.08 (-11.86%)
As of 09/16/2026 09:32 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$1.76 -0.18 (-9.28%)
Closing price 09/16/2026 03:59 PM Eastern
Extended Trading
$1.75 -0.01 (-0.34%)
As of 09/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$4.68 -0.08 (-1.68%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$4.78 +0.10 (+2.03%)
As of 09/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas